<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36215050</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.</ArticleTitle><Pagination><StartPage>1155</StartPage><EndPage>1164</EndPage><MedlinePgn>1155-1164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.3265</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Biomarkers are lacking that can discriminate frontotemporal lobar degeneration (FTLD) associated with tau (FTLD-tau) or TDP-43 (FTLD-TDP).</AbstractText><AbstractText Label="OBJECTIVE">To test whether plasma biomarkers glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), or their ratio (GFAP/NfL) differ between FTLD-tau and FTLD-TDP.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This retrospective cross-sectional study included data from 2009 to 2020 from the University of Pennsylvania Integrated Neurodegenerative Disease Database, with a median (IQR) follow-up duration of 2 (0.3-4.2) years. The training sample was composed of patients with autopsy-confirmed and familial FTLD; nonimpaired controls were included as a reference group. The independent validation sample included patients with FTD with a clinical diagnosis of progressive supranuclear palsy syndrome (PSPS) associated with tau (PSPS-tau) or amytrophic lateral sclerosis (ALS) associated with TDP-43 (ALS-TDP). In patients with FTLD with autopsy-confirmed or variant-confirmed pathology, receiver operating characteristic (ROC) curves tested the GFAP/NfL ratio and established a pathology-confirmed cut point. The cut point was validated in an independent sample of patients with clinical frontotemporal dementia (FTD). Data were analyzed from February to July 2022.</AbstractText><AbstractText Label="EXPOSURES">Clinical, postmortem histopathological assessments, and plasma collection.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">ROC and area under the ROC curve (AUC) with 90% CIs evaluated discrimination of pure FTLD-tau from pure FTLD-TDP using plasma GFAP/NfL ratio; the Youden index established optimal cut points. Sensitivity and specificity of cut points were assessed in an independent validation sample.</AbstractText><AbstractText Label="RESULTS">Of 349 participants with available plasma data, 234 met inclusion criteria (31 controls, 141 in the training sample, and 62 in the validation sample). In the training sample, patients with FTLD-tau were older than patients with FTLD-TDP (FTLD-tau: n&#x2009;=&#x2009;46; mean [SD] age, 65.8 [8.29] years; FTLD-TDP: n&#x2009;=&#x2009;95; mean [SD] age, 62.3 [7.82] years; t84.6&#x2009;=&#x2009;2.45; mean difference, 3.57; 95% CI, 0.67-6.48; P&#x2009;=&#x2009;.02) but with similar sex distribution (FTLD-tau: 27 of 46 [59%] were male; FTLD-TDP: 51 of 95 [54%] were male; &#x3c7;21&#x2009;=&#x2009;0.14; P&#x2009;=&#x2009;.70). In the validation sample, patients with PSPS-tau were older than those with ALS-TDP (PSPS-tau: n&#x2009;=&#x2009;31; mean [SD] age, 69.3 [7.35] years; ALS-TDP: n&#x2009;=&#x2009;31; mean [SD] age, 54.6 [10.17] years; t54.6&#x2009;=&#x2009;6.53; mean difference, 14.71; 95% CI, 10.19-19.23; P&#x2009;&lt;&#x2009;.001) and had fewer patients who were male (PSPS-tau: 9 of 31 [29%] were male; ALS-TDP: 22 of 31 [71%] were male; &#x3c7;21&#x2009;=&#x2009;9.3; P&#x2009;=&#x2009;.002). ROC revealed excellent discrimination of FTLD-tau from FTLD-TDP by plasma GFAP/NfL ratio (AUC&#x2009;=&#x2009;0.89; 90% CI, 0.82-0.95; sensitivity&#x2009;=&#x2009;0.73; 90% CI, 0.65-0.89; specificity&#x2009;=&#x2009;0.89; 90% CI, 0.78-0.98), which was higher than either GFAP level alone (AUC&#x2009;=&#x2009;0.65; 90% CI, 0.54-0.76) or NfL levels alone (AUC&#x2009;=&#x2009;0.75; 90% CI, 0.64-0.85). In the validation sample, there was sensitivity of 0.84 (90% CI, 0.66-0.94) and specificity of 0.81 (90% CI, 0.62-0.91) when applying the autopsy-derived plasma GFAP/NfL threshold.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">The plasma ratio of GFAP/NfL may discriminate FTLD-tau from FTLD-TDP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cousins</LastName><ForeName>Katheryn A Q</ForeName><Initials>KAQ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen-Plotkin</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS082265</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS115139</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Cousins has received grants from the Alzheimer&#x2019;s Association and University of Pennsylvania&#x2019;s Alzheimer&#x2019;s Disease Research Center during the conduct of the study. Dr Shaw has received grants from the National Institute on Aging during the conduct of the study and has received personal fees from Biogen and Fujirebio outside the submitted work. Dr Chen-Plotkin has received grants from the National Institutes of Health, Michael J. Fox Foundation/Alzheimer&#x2019;s Association, American Heart Association/Allen Institute, and Chan Zuckerberg Initiative and support from an endowed chair from the Parker Family outside the submitted work. Dr Wolk has received grants from the National Institute on Aging during the conduct of the study; grants from Biogen and Merck; personal fees from Functional Neuromodulation, Qynapse, Eli Lilly, Neuronix, and GE Healthcare outside the submitted work. Dr Lee has received grants from the National Institutes of Health during the conduct of the study. Dr Grossman has received grants from the National Institutes of Health, Department of Defense, and Samuel Newhouse Foundation during the conduct of the study. Dr Irwin has received grants from the National Institutes of Health during the conduct of the study and is a member of the scientific advisory board of Denali Therapeutics outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>10</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36215050</ArticleId><ArticleId IdType="pmc">PMC9552044</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.3265</ArticleId><ArticleId IdType="pii">2796817</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seelaar H, Rohrer JD, Pijnenburg YAL, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82(5):476-486. doi:10.1136/jnnp.2010.212225</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.212225</ArticleId><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol. 2015;41(7):858-881. doi:10.1111/nan.12250</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12250</ArticleId><ArticleId IdType="pubmed">26041104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Boeve BF, Boxer AL. Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: recent findings from ARTFL and LEFFTDS. Alzheimers Dement. 2020;16(1):71-78. doi:10.1002/alz.12004</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12004</ArticleId><ArticleId IdType="pmc">PMC6953606</ArticleId><ArticleId IdType="pubmed">31914219</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA Research Framework: toward a biological definition of Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;glinger GU, Respondek G, Stamelou M, et al. ; Movement Disorder Society-endorsed PSP Study Group . Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society Criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pmc">PMC5516529</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Z, Irish M, Hodges JR, Halliday G, Piguet O, Burrell JR. Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration. Neurobiol Aging. 2021;107:11-20. doi:10.1016/j.neurobiolaging.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.07.004</ArticleId><ArticleId IdType="pubmed">34371283</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Farmer J, Johnson JK, et al. . Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59(6):952-962. doi:10.1002/ana.20873</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20873</ArticleId><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Hodges JR, Snowden JS, et al. . Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122(2):137-153. doi:10.1007/s00401-011-0839-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0839-6</ArticleId><ArticleId IdType="pmc">PMC3232515</ArticleId><ArticleId IdType="pubmed">21614463</ArticleId></ArticleIdList></Reference><Reference><Citation>Murley AG, Coyle-Gilchrist I, Rouse MA, et al. . Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes. Brain. 2020;143(5):1555-1571. doi:10.1093/brain/awaa097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa097</ArticleId><ArticleId IdType="pmc">PMC7241953</ArticleId><ArticleId IdType="pubmed">32438414</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarioni M, Gami-Patel P, Timar Y, et al. ; Netherlands Brain Bank . Frontotemporal dementia: correlations between psychiatric symptoms and pathology. Ann Neurol. 2020;87(6):950-961. doi:10.1002/ana.25739</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25739</ArticleId><ArticleId IdType="pmc">PMC7318614</ArticleId><ArticleId IdType="pubmed">32281118</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075-2086. doi:10.1007/s00415-019-09363-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09363-4</ArticleId><ArticleId IdType="pmc">PMC6647117</ArticleId><ArticleId IdType="pubmed">31119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin D. Preparing for the age of therapeutic trials in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2022;93(2):115. doi:10.1136/jnnp-2021-327497</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327497</ArticleId><ArticleId IdType="pmc">PMC8967129</ArticleId><ArticleId IdType="pubmed">34408005</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Campo M, Zetterberg H, Gandy S, et al. . New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. Published online March 2, 2022. doi:10.1002/alz.12643</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12643</ArticleId><ArticleId IdType="pmc">PMC9790674</ArticleId><ArticleId IdType="pubmed">35235699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, Irwin DJ, Ill&#xe1;n-Gala I, et al. . A 2-step cerebrospinal algorithm for the selection of frontotemporal lobar degeneration subtypes. JAMA Neurol. 2018;75(6):738-745. doi:10.1001/jamaneurol.2018.0118</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0118</ArticleId><ArticleId IdType="pmc">PMC5885205</ArticleId><ArticleId IdType="pubmed">29554190</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Lle&#xf3; A, Xie SX, et al. . Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Ann Neurol. 2017;82(2):247-258. doi:10.1002/ana.24996</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24996</ArticleId><ArticleId IdType="pmc">PMC5776747</ArticleId><ArticleId IdType="pubmed">28719018</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, et al. . Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):442-448. doi:10.1001/jamaneurol.2013.6064</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6064</ArticleId><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Borroni B, Benussi A, Archetti S, et al. . Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):86-91. doi:10.3109/21678421.2014.971812</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.971812</ArticleId><ArticleId IdType="pubmed">25352065</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LHH, Vijverberg EG, Del Campo M, et al. . Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231-e1239. doi:10.1212/WNL.0000000000005261</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005261</ArticleId><ArticleId IdType="pmc">PMC5890612</ArticleId><ArticleId IdType="pubmed">29514947</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Mometto N, Bartoletti-Stella A, et al. . Cerebrospinal fluid biomarkers in patients with frontotemporal dementia spectrum: a single-center study. J Alzheimers Dis. 2018;66(2):551-563. doi:10.3233/JAD-180409</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180409</ArticleId><ArticleId IdType="pubmed">30320576</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg YALL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015;1(4):505-512. doi:10.1016/j.dadm.2015.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2015.11.001</ArticleId><ArticleId IdType="pmc">PMC4879490</ArticleId><ArticleId IdType="pubmed">27239528</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126(5):659-670. doi:10.1007/s00401-013-1151-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1151-4</ArticleId><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller C, Foiani MS, Moore K, et al. ; GENFI . Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(3):263-270. doi:10.1136/jnnp-2019-321954</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321954</ArticleId><ArticleId IdType="pubmed">31937580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I, Lleo A, Karydas A, et al. . Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology. 2021;96(5):e671-e683. doi:10.1212/WNL.0000000000011226</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011226</ArticleId><ArticleId IdType="pmc">PMC7884995</ArticleId><ArticleId IdType="pubmed">33199433</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res. 2000;25(9-10):1439-1451. doi:10.1023/A:1007677003387</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1007677003387</ArticleId><ArticleId IdType="pubmed">11059815</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4(3):229-237. doi:10.1111/j.1750-3639.1994.tb00838.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1994.tb00838.x</ArticleId><ArticleId IdType="pubmed">7952264</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589. doi:10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie SX, Baek Y, Grossman M, et al. . Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement. 2011;7(4):e84-e93. doi:10.1016/j.jalz.2010.08.233</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.08.233</ArticleId><ArticleId IdType="pmc">PMC3145967</ArticleId><ArticleId IdType="pubmed">21784346</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Van Deerlin VM, Lee EB, et al. . A platform for discovery: the University of Pennsylvania Integrated Neurodegenerative Disease biobank. Alzheimers Dement. 2014;10(4):477-484.e1. doi:10.1016/j.jalz.2013.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.06.003</ArticleId><ArticleId IdType="pmc">PMC3933464</ArticleId><ArticleId IdType="pubmed">23978324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB. Integrated neurodegenerative disease autopsy diagnosis. Acta Neuropathol. 2018;135(4):643-646. doi:10.1007/s00401-018-1827-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1827-x</ArticleId><ArticleId IdType="pmc">PMC6186396</ArticleId><ArticleId IdType="pubmed">29502201</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem. 2016;138(suppl 1):6-31. doi:10.1111/jnc.13654</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13654</ArticleId><ArticleId IdType="pubmed">27144467</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousins KAQ, Irwin DJ, Wolk DA, et al. . ATN status in amnestic and non-amnestic Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Brain. 2020;143(7):2295-2311. doi:10.1093/brain/awaa165</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa165</ArticleId><ArticleId IdType="pmc">PMC7364757</ArticleId><ArticleId IdType="pubmed">32666090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood EM, Falcone D, Suh E, et al. . Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 2013;70(11):1411-1417. doi:10.1001/jamaneurol.2013.3956</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.3956</ArticleId><ArticleId IdType="pmc">PMC3906581</ArticleId><ArticleId IdType="pubmed">24081456</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3):384-389. doi:10.1007/s12031-011-9589-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9589-0</ArticleId><ArticleId IdType="pmc">PMC3208128</ArticleId><ArticleId IdType="pubmed">21720721</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M, Baborie A, et al. . A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111-113. doi:10.1007/s00401-011-0845-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. ; National Institute on Aging; Alzheimer&#x2019;s Association . National Institute on Aging-Alzheimer&#x2019;s Association guidelines for the neuropathologic assessment of Alzheimer&#x2019;s disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0910-3</ArticleId><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Boeve BF, Dickson DW, et al. . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004058</ArticleId><ArticleId IdType="pmc">PMC5496518</ArticleId><ArticleId IdType="pubmed">28592453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, et al. . Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134(1):65-78. doi:10.1007/s00401-017-1679-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1679-9</ArticleId><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea TF, Waligorska T, Xie SX, et al. . Plasma phosphorylated Tau181 is a biomarker of Alzheimer&#x2019;s disease pathology and associated with cognitive and functional decline. SSRN. Preprint posted online January 20, 2022. doi:10.2139/ssrn.4007185</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4007185</ArticleId></ArticleIdList></Reference><Reference><Citation>Waligorska T, Figurski MJ, Jeromin A, Chen-Plotkin A, Trojanowski JQ, Shaw LM. P3-232: Validation studies of neurofilament light and a&#x3b2;-40 and a&#x3b2;-42 assays in human plasma using the Simoa platform. Alzheimers Dement. 2019;15(7S):P1022. doi:10.1016/j.jalz.2019.06.3262</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.06.3262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Woollacott IOC, Dick KM, et al. . Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329-1336. doi:10.1212/WNL.0000000000003154</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003154</ArticleId><ArticleId IdType="pmc">PMC5047041</ArticleId><ArticleId IdType="pubmed">27581216</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee P, Pedrini S, Stoops E, et al. . Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer&#x2019;s disease. Transl Psychiatry. 2021;11(1):27. doi:10.1038/s41398-020-01137-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-020-01137-1</ArticleId><ArticleId IdType="pmc">PMC7801513</ArticleId><ArticleId IdType="pubmed">33431793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413. doi:10.1002/ana.21610</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A, Wellington H, Chen Z, et al. . Concordance of CSF measures of Alzheimer&#x2019;s pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays. Alzheimers Dement (Amst). 2021;13(1):e12131. doi:10.1002/dad2.12131</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12131</ArticleId><ArticleId IdType="pmc">PMC7867115</ArticleId><ArticleId IdType="pubmed">33598527</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121(5):597-609. doi:10.1007/s00401-011-0808-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0808-0</ArticleId><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele C, Hirschfeld G. Cutpointr: improved estimation and validation of optimal cutpoints in R. J Stat Softw. 2021;98(11):1-27. doi:10.18637/jss.v098.i11</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v098.i11</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Shachar M, L&#xfc;decke D, Makowski D. effectsize: estimation of effect size indices and standardized parameters. J Open Source Softw. 2020;5(56):2815. doi:10.21105/joss.02815</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.02815</ArticleId></ArticleIdList></Reference><Reference><Citation>Olejnik S, Algina J. Generalized eta and omega squared statistics: measures of effect size for some common research designs. Psychol Methods. 2003;8(4):434-447. doi:10.1037/1082-989X.8.4.434</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.8.4.434</ArticleId><ArticleId IdType="pubmed">14664681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JB, Janelidze S, Smith R, et al. . Plasma GFAP is an early marker of amyloid-&#x3b2; but not tau pathology in Alzheimer&#x2019;s disease. Brain. 2021;144(11):3505-3516. doi:10.1093/brain/awab223</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab223</ArticleId><ArticleId IdType="pmc">PMC8677538</ArticleId><ArticleId IdType="pubmed">34259835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashton NJ, Janelidze S, Al Khleifat A, et al. . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400. doi:10.1038/s41467-021-23620-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23620-z</ArticleId><ArticleId IdType="pmc">PMC8185001</ArticleId><ArticleId IdType="pubmed">34099648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, et al. . Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247-2257. doi:10.1212/WNL.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, O&#x2019;Reilly EJ, Molsberry S, et al. . Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis. Neurology. 2021;97(15):e1466-e1474. doi:10.1212/WNL.0000000000012632</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012632</ArticleId><ArticleId IdType="pmc">PMC8575132</ArticleId><ArticleId IdType="pubmed">34380747</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer&#x2019;s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst). 2019;11:730-743. doi:10.1016/j.dadm.2019.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.08.009</ArticleId><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini LAA, Peterson C, Ohm D, et al. . Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta Neuropathol Commun. 2021;9(1):30. doi:10.1186/s40478-021-01129-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01129-2</ArticleId><ArticleId IdType="pmc">PMC7901087</ArticleId><ArticleId IdType="pubmed">33622418</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm DT, Cousins KAQ, Xie SX, et al. . Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathol. 2022;143(3):363-382. doi:10.1007/s00401-021-02402-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02402-3</ArticleId><ArticleId IdType="pmc">PMC8858288</ArticleId><ArticleId IdType="pubmed">34997851</ArticleId></ArticleIdList></Reference><Reference><Citation>Bright F, Werry EL, Dobson-Stone C, et al. . Neuroinflammation in frontotemporal dementia. Nat Rev Neurol. 2019;15(9):540-555. doi:10.1038/s41582-019-0231-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0231-z</ArticleId><ArticleId IdType="pubmed">31324897</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AG, Webster JA, Hales CM. Glial profiling of human tauopathy brain demonstrates enrichment of astrocytic transcripts in tau-related frontotemporal degeneration. Neurobiol Aging. 2022;112:55-73. doi:10.1016/j.neurobiolaging.2021.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.12.005</ArticleId><ArticleId IdType="pmc">PMC8976718</ArticleId><ArticleId IdType="pubmed">35051675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiki A, Kamada M, Kawamura Y, et al. . Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer&#x2019;s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258-261. doi:10.1111/jnc.13399</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13399</ArticleId><ArticleId IdType="pubmed">26485083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, Santos-Santos M, Ill&#xe1;n-Gala I, et al. . Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Transl Neurodegener. 2021;10(1):50. doi:10.1186/s40035-021-00275-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00275-w</ArticleId><ArticleId IdType="pmc">PMC8662866</ArticleId><ArticleId IdType="pubmed">34893073</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, van Swieten JC. Fluid biomarkers of frontotemporal lobar degeneration. In: Ghetti B, Buratti E, Boeve B, Rademakers R, eds. Frontotemporal Dementias: Emerging Milestones of the 21st Century. Springer International Publishing; 2021:123-139. doi:10.1007/978-3-030-51140-1_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-51140-1_9</ArticleId><ArticleId IdType="pubmed">33433873</ArticleId></ArticleIdList></Reference><Reference><Citation>Simr&#xe9;n J, Leuzy A, Karikari TK, et al. ; AddNeuroMed consortium . The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer&#x2019;s disease. Alzheimers Dement. 2021;17(7):1145-1156. doi:10.1002/alz.12283</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12283</ArticleId><ArticleId IdType="pmc">PMC8359457</ArticleId><ArticleId IdType="pubmed">33491853</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedet AL, Mil&#xe0;-Alom&#xe0; M, Vrillon A, et al. ; Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer&#x2019;s and Families (ALFA) study, and BioCogBank Paris Lariboisi&#xe8;re cohort . Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78(12):1471-1483. doi:10.1001/jamaneurol.2021.3671</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.3671</ArticleId><ArticleId IdType="pmc">PMC8524356</ArticleId><ArticleId IdType="pubmed">34661615</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicognola C, Janelidze S, Hertze J, et al. . Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1):68. doi:10.1186/s13195-021-00804-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00804-9</ArticleId><ArticleId IdType="pmc">PMC8005231</ArticleId><ArticleId IdType="pubmed">33773595</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Bron EE, Poos JM, et al. ; GENFI consortium . A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain. 2022;145(5):1805-1817. doi:10.1093/brain/awab382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab382</ArticleId><ArticleId IdType="pmc">PMC9166533</ArticleId><ArticleId IdType="pubmed">34633446</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Wang P, Staffaroni AM, et al. ; ALLFTD and GENFI consortia . Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology. 2021;96(18):e2296-e2312. doi:10.1212/WNL.0000000000011848</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011848</ArticleId><ArticleId IdType="pmc">PMC8166434</ArticleId><ArticleId IdType="pubmed">33827960</ArticleId></ArticleIdList></Reference><Reference><Citation>Heller C, Chan E, Foiani MS, et al. . Plasma glial fibrillary acidic protein and neurofilament light chain are measures of disease severity in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2020;92(4):455-456. doi:10.1136/jnnp-2020-325085</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325085</ArticleId><ArticleId IdType="pubmed">33219041</ArticleId></ArticleIdList></Reference><Reference><Citation>Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer&#x2019;s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123(pt 3):484-498. doi:10.1093/brain/123.3.484</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.3.484</ArticleId><ArticleId IdType="pubmed">10686172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, McGinnis SM, Xia C, et al. . Approach to atypical Alzheimer&#x2019;s disease and case studies of the major subtypes. CNS Spectr. 2017;22(6):439-449. doi:10.1017/S109285291600047X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S109285291600047X</ArticleId><ArticleId IdType="pmc">PMC5557706</ArticleId><ArticleId IdType="pubmed">28196556</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Yong KXX, Apostolova LG, et al. . New insights into atypical Alzheimer&#x2019;s disease in the era of biomarkers. Lancet Neurol. 2021;20(3):222-234. doi:10.1016/S1474-4422(20)30440-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30440-3</ArticleId><ArticleId IdType="pmc">PMC8056394</ArticleId><ArticleId IdType="pubmed">33609479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cousins KAQ, Shaw LM, Shellikeri S, et al. . Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis. Ann Neurol. Published online July 25, 2022. doi:10.1002/ana.26462</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26462</ArticleId><ArticleId IdType="pmc">PMC9588516</ArticleId><ArticleId IdType="pubmed">35877814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>